Form 4: Aclaris Therapeutics Director Andrew Schiff Reports Transaction in Company Stock
SEC Form 4 Filing
Director Andrew Schiff reports a transaction involving Aclaris Therapeutics common stock, including the vesting of restricted stock units and shares held indirectly through Aisling Capital IV, LP.
Summary
- On June 1, 2024, Andrew Schiff, a director of Aclaris Therapeutics, reported a transaction involving the company's common stock.
- The transaction included the vesting of 4,660 restricted stock units, each representing a contingent right to receive one share of common stock.
- Schiff also reported indirect beneficial ownership of 434,455 shares held by Aisling Capital IV, LP.
- Schiff disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
- A power of attorney was executed on May 16, 2024, granting certain individuals the authority to file SEC forms on Schiff's behalf.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, so the sentiment is neither positive nor negative.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of execution of Power of Attorney. |
| 06/01/2024 | Date of transaction involving common stock and vesting of restricted stock units. |
| 06/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.